Journal article

Publication year: 2017

Pages: 127-133

Journal: International Journal of Cardiology

Volume number: 227

ISSN: 0167-5273

eISSN: 1874-1754

DOI Link: https://doi.org/10.1016/j.ijcard.2016.11.033

Publisher: Elsevier

Abstract: 
The DESolve scaffold (Elixir Medical Corporation, Sunnyvale, California, USA) is manufactured from a poly-ilactide based polymer and elutes an anti-proliferative, anti-inflammatory drug, Novolimus from a poly-L-lactide based topcoat mixture. The strut thickness is 150 lam and the scaffold has platinum-iridium radiopaque markers at both ends. Radial support is available during the early time period to prevent recoil The scaffold biodegrades within 1 year (>90% reduction in molecular weight) and then completely bioresorbs within 2 years. The DESolve scaffold permits a wide range of expansion with a consequently reduced risk for strut fracture. Lumen and scaffold enlargement is observed within 3-6 months in both preclinical and clinical studies potentially allowing for the scaffolded region to respond to vasoactive stimuli. The device has a unique property of self-correction observed in bench top studies, which in clinical practice has the potential to eliminate minor malapposition following deployment. (C) 2016 Elsevier Ireland Ltd. All rights reserved.

Harvard Citation style: Nef, H., Wiebe, J., Foin, N., Blachutzik, F., Doerr, O., Toyloy, S., et al. (2017) A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives, International Journal of Cardiology, 227, pp. 127-133. https://doi.org/10.1016/j.ijcard.2016.11.033

APA Citation style: Nef, H., Wiebe, J., Foin, N., Blachutzik, F., Doerr, O., Toyloy, S., & Hamm, C. (2017). A new novolimus-eluting bioresorbable coronary scaffold: Present status and future clinical perspectives. International Journal of Cardiology. 227, 127-133. https://doi.org/10.1016/j.ijcard.2016.11.033